Journal of Affective Disorders
Volume 105, Issue 1 , Pages 101-108 , January 2008

Olanzapine versus lithium in the acute treatment of bipolar mania: A double-blind, randomized, controlled trial

  • Gu Niufan

      Affiliations

    • Shanghai Mental Health Center, Shanghai, People's Republic of China
    • ,
  • Mauricio Tohen

      Affiliations

    • Lilly Research Laboratories, Indianapolis, Indiana, USA
    • McLean Hospital, Harvard Medical School, Belmont MA, USA
    • Corresponding Author InformationCorresponding author. Lilly Research Laboratories, Indianapolis, IN 46285, USA. Tel.: +1 317 277 9585; fax: +1 317 276 7845.
    • ,
  • Ang Qiuqing

      Affiliations

    • Eli Lilly Asia, Shanghai, People's Republic of China
    • ,
  • Yang Fude

      Affiliations

    • Beijing Hui Long Guan Hospital, Beijing, People's Republic of China
    • ,
  • Elizabeth Pope

      Affiliations

    • Eli Lilly Australia, New South Wales, Australia
    • ,
  • Heather McElroy

      Affiliations

    • Eli Lilly Australia, New South Wales, Australia
    • ,
  • Li Ming

      Affiliations

    • Suzhou Psychiatric Hospital, Suzhou, People's Republic of China
    • ,
  • Wang Gaohua

      Affiliations

    • Renmin Hospital of Wuhan University, Wuhan, People's Republic of China
    • ,
  • Zhang Xinbao

      Affiliations

    • Nanjing Brain Hospital, Nanjing, People's Republic of China
    • ,
  • Li Huichun

      Affiliations

    • 2nd Affiliated Hospital of Zhejiang University College of Medicine, Hangzhou, People's Republic of China
    • ,
  • Shu Liang

      Affiliations

    • Institute of Mental Health, Peking University, Beijing, People's Republic of China

Received 7 December 2006 ,Revised 15 April 2007 ,Accepted 24 April 2007.

References 

  1. [APA] American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders. 4th ed.. Washington, DC: American Psychiatric Association; 1994;
  2. Berk M, Ichim L, Brook S. Olanzapine compared to lithium in mania: a double-blind randomized controlled trial. Int. Clin. Psychopharmacol. 1999;14:339–343
  3. Fountoulakis KN, Vieta E, Sanchez-Moreno J, Kaprinis SG, Goikolea JM, Kaprinis GS. Treatment guidelines for bipolar disorder: a critical review. J. Affect. Disord. 2005;86:1–10
  4. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry. 1979;134:382–389
  5. Overall JE, Gorham DR. The brief psychiatric rating scale (BPRS): recent developments in ascertainment and scaling. Psychopharmacol. Bull. 1988;24:97–99
  6. Sathirakul K, Chan C, Teng L, Bergstrom RF, Poo Yeo K, Wise SD. Olanzapine pharmacokinetics are similar in Chinese and Caucasian subjects. Br. J. Clin. Pharmacol. 2003;56:184–187
  7. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand. 1970;212(Suppl 44):11–19
  8. Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W. Modification of the Clinical Global Impressions (CGI) scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res. 1997;73:159–171
  9. Tohen M, Sanger TM, McElroy SL, Tollefson GD, Chengappa KN, Daniel DG, et al. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am. J. Psychiatry. 1999;156:702–709
  10. Tohen M, Jacobs TG, Grundy SL, McElroy SL, Banov MC, Janicak PG, et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzapine HGGW Study Group. Arch. Gen. Psychiatry. 2000;57:841–849
  11. Tohen M, Baker RW, Altshuler LA, Zarate CA, Suppes T, Ketter TA, et al. Olanzapine versus divalproex for the treatment of acute mania. Am. J. Psychiatry. 2002;159(6):1011–1017
  12. Tohen M, Goldberg JF, Gonzalez-Pinto AM, Azorin JM, Vieta E, Hardy-Bayle MC, et al. A 12-week double-blind comparison of olanzapine versus haloperidol in the treatment of acute mania. Arch. Gen. Psychiatry. 2003;60:1218–1226
  13. Tohen M, Griel W, Calabrese JR, Sachs GS, Yatham LN, Müller Oerlinghausen B, et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled trial. Am. J. Psychiatry. 2005;162:1281–1290
  14. Tohen M, Calabrese JR, Sachs GS, Banov MD, Detke HC, Risser R, et al. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am. J. Psychiatry. 2006;163:247–256
  15. Young RC, Biggs JT, Ziegler VT, Meyer DA. A rating scale for mania: reliability, validity, and sensitivity. Br. J. Psychiatry. 1978;133:429–435
  16. Zhang M, Wu W, Zhu C. Handbook of Rating Scales in Psychiatry. Hunan: Hunan Science and Technology Press; 1993;[Chinese]

☆ Conflict of interest. This study was sponsored by Eli Lilly and Company. M. Tohen, A. Qiuqing, H. McElroy, and E. Pope are employees of Eli Lilly and Company. G. Niufan, Y. Fude, L. Ming, W. Gaohua, Z. Xinbao, L. Huichun, and S. Liang are clinical investigators for the F1D-GH-LOBV study (upon which the manuscript is based), for which their institutions were funded by Eli Lilly and Company for the time spent and assessment cost. The authors have no other potential conflicts of interest to disclose.Contributors. M. Tohen and A. Qiuqing were involved in the conception and design of the study. H. McElroy undertook the statistical analyses. E. Pope conducted the literature searches, and drafted the manuscript. G. Niufan, Y. Fude, L. Ming, W. Gaohua, Z. Xinbao, L. Huichun, and S. Liang were involved in the acquisition of data. All authors contributed to the interpretation of the data, critical revision of the manuscript for important intellectual content, and have approved the final manuscript.Role of funding source. Eli Lilly and Company (Lilly) provided funding for this study and was involved in the study conception and design. Lilly had no role in the collection of data for this particular manuscript, beyond the provision of clinical report forms and undertaking clinical monitoring of study sites. Lilly was involved in the analysis and interpretation of data for this manuscript, and in the drafting of the manuscript. Outside of the Lilly employees listed as authors (M. Tohen, A. Qiuqing, H. McElroy, and E. Pope), Lilly had no role in the decision to submit the paper for publication.

PII: S0165-0327(07)00144-9

doi: 10.1016/j.jad.2007.04.020

Journal of Affective Disorders
Volume 105, Issue 1 , Pages 101-108 , January 2008

Article Tools

* Image Usage & Resolution